Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: June 11, 2010
Last updated: June 5, 2016
Last verified: June 2016